Neurocrine Biosciences Inc. (NASDAQ:NBIX)’s share price traded up 3.7% during trading on Monday . The company traded as high as $50.43 and last traded at $50.38, with a volume of 377,073 shares. The stock had previously closed at $48.57.

Several brokerages have weighed in on NBIX. Jefferies Group reissued a “buy” rating on shares of Neurocrine Biosciences in a research report on Sunday, May 8th. Robert W. Baird reissued a “buy” rating on shares of Neurocrine Biosciences in a research report on Sunday, May 8th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Neurocrine Biosciences in a research report on Wednesday, May 4th. Leerink Swann reissued an “outperform” rating and set a $63.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, June 1st. Finally, Cowen and Company reiterated a “buy” rating and issued a $65.00 price target on shares of Neurocrine Biosciences in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. Neurocrine Biosciences has an average rating of “Buy” and an average target price of $63.90.

The firm’s 50 day moving average price is $48.79 and its 200-day moving average price is $44.04. The stock’s market capitalization is $4.53 billion.

In related news, Director Corinne H. Nevinny sold 5,000 shares of the company’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $48.54, for a total value of $242,700.00. Following the completion of the sale, the director now directly owns 25,555 shares of the company’s stock, valued at $1,240,439.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Christopher Flint Obrien sold 12,500 shares of the company’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $48.73, for a total transaction of $609,125.00. Following the completion of the sale, the insider now directly owns 55,044 shares of the company’s stock, valued at $2,682,294.12. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Neurocrine Biosciences stock. BlackRock Advisors LLC raised its position in Neurocrine Biosciences Inc. (NASDAQ:NBIX) by 28.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,069,299 shares of the company’s stock after buying an additional 235,700 shares during the period. BlackRock Advisors LLC owned approximately 1.24% of Neurocrine Biosciences worth $60,490,000 as of its most recent SEC filing.

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.